Please login to the form below

Not currently logged in
Email:
Password:

drug rebates

This page shows the latest drug rebates news and features for those working in and with pharma, biotech and healthcare.

Europe's market access outlook

Europe's market access outlook

G20 Summit in China to continue its campaign for wider international collaboration to control drug prices. ... Details of drug rebates will, in future, be available only to institutions of the German healthcare system that require this information to

Latest news

  • UK pharma's contribution to NHS hits £1bn mark UK pharma's contribution to NHS hits £1bn mark

    UK pharma's contribution to NHS hits £1bn mark. ABPI says local access to new treatments still not universal despite drug rebates. ... The idea is to help make new drug treatments more affordable for the NHS and give UK patients the same level of access

  • The Italian Job The Italian Job

    More rebates are due if Harvard Pilgrim's spending on the drug surpasses an agreed-upon threshold. ... When a country gets rebates totalling 1% of their drug budget, it means that a lot of therapies did not work for a lot of patients.

  • Pfizer settles US Protonix lawsuit for $785m Pfizer settles US Protonix lawsuit for $785m

    Pfizer settles US Protonix lawsuit for $785m. US government deal covers Wyeth’ s failure to pay drug rebates. ... After years of legal wrangling, Pfizer has finally agreed to pay $785m to settle a lawsuit claiming its Wyeth unit failed to pay rebates

  • US government probes Lilly and Merck over drug pricing US government probes Lilly and Merck over drug pricing

    US government probes Lilly and Merck over drug pricing. Department of Justice investigates drug pricing with regard to Medicaid programme. ... The drug pricing debate rumbling along in the US has taken another turn, with both Merck &Co and Eli Lilly

  • France agrees lowest Sovaldi pricing in EU France agrees lowest Sovaldi pricing in EU

    well as rebates on the drug's cost in cases of treatment failure. ... of the drug, with no patient co-pay, to help make it affordable for citizens with HCV infection.

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Market access in Europe: balancing access and affordability Market access in Europe: balancing access and affordability

    However, if sales in that period exceed 250m, companies will be liable to pay rebates. ... In response to the pharmaceutical industry's concerns about international reference pricing, details of drug rebates will, in future, be available only to

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
McCann Health

The most globally awarded health agency network and currently Health Network agency of The Year. Comprising of two specialist agencies:...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics